Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Options Trading Strategies on Pfizer: Two Tactics for Advanced Traders
In the options market, some movements reveal hidden opportunities for experienced traders. Pfizer has recently attracted attention with unusual activity suggesting specific options trading strategies. Data analysis shows how two distinct approaches can exploit this volatility in opposite directions, both potentially profitable.
The PFE Options Anomaly: What the Data Indicates
Unusual activity on Pfizer (PFE) reached extraordinary levels during a recent trading session. The $29 put expiring on March 20 had a volume/open interest (Vol/OI) ratio of 210.16, surpassing the next most active option by 35%. With 30,263 contracts traded versus only 144 open interest, the signal is clear: investors and traders are focusing significant resources on this particular position.
Pfizer, with a market cap of $144 billion, has recently offered little reason for optimism. Once a symbol of the pandemic boom, the stock has significantly shrunk. The $61.71 peak in 2021 is now distant history: the current price of $25.43 reflects a 59% decline from those levels. For investors seeking a rebound, the challenge remains substantial.
The trading session showed total activity equal to 1.39 times the 30-day average volume of 142,695 contracts, marking the most active day since December 17. Although below the quarterly peak of 890,898 contracts recorded after the Q3 2025 earnings release (November 4), activity remains notable. The December 16 update, where Pfizer confirmed its 2025 outlook and lowered 2026 forecasts to a $2.90 EPS, initiated the downward movement that continues to influence valuations.
Long Straddle: Betting on Volatility
The simultaneous activity observed on the $29 put and call, both expiring on March 20, reveals a specific strategy: the long straddle. This options trading approach is based on a simple but powerful premise: profit from high volatility regardless of the movement’s direction.
Holding both a call and a put at the same strike, the trader accepts an initial cost to gain exposure to significant moves in both directions. For this setup, the net debit is $4.38, with breakeven points at $33.38 (upside) and $24.62 (downside).
Success probabilities are around 37%, not particularly high, but offset by the favorable timeframe: 71 days until expiration. Experienced traders generally prefer 30-45 days, as this allows for meaningful movement without excessive time decay. With an expected 6.96% move in either direction, the price could reach $27.05 downward, generating an $89 profit. Annualized, this yields a 128.0% return, calculated as ($109 gain / $438 net debit × 365 / 71 days).
The long straddle is especially useful for operators anticipating volatility but unsure of the direction. It does not require a strong directional view but rather an expectation of broad movement.
Bull Put Spread: The Bullish Approach
The second emerging options trading strategy from the data is the bull put spread, a position with a decidedly bullish outlook on Pfizer. This tactic involves selling the $29 put, earning a premium of $390, while buying a $26 put as protection for $156. The resulting net credit is $234.
The maximum theoretical loss is limited to $66, calculated as: [$29 strike short put - $26 strike long put] × 100 + $234 net credit. This creates a risk/reward ratio of 0.28 to 1, meaning the trader risks $28 for every $100 potentially gained.
If Pfizer closes above $29 at the March 20 expiration, the entire position expires worthless, and the maximum profit of $234 is realized—a 354.55% return, equivalent to an 1,848.73% annualized rate. Although the success probability is roughly one in three, the breakeven point at $26.66 is only 4.84% above the current price. Profits are possible even if the stock ends between $26.66 and $29.
This options trading strategy is more conservative than the long straddle, as it requires a move in the expected direction but not necessarily a dramatic one. The protection from the $26 put limits downside risk, appealing to operators with moderate risk tolerance.
Comparing the Two Strategies
Choosing between these two options trading strategies depends on the trader’s profile. The long straddle suits those expecting significant movement but neutral on direction—ideal for pre-earnings scenarios or during geopolitical uncertainty. It offers potential gains in both directions but requires substantial movement to offset the initial cost.
Conversely, the bull put spread is suitable for operators with a moderate bullish outlook and limited risk appetite. It generates immediate income and only needs a modest upward move to reach maximum profitability. The success probability, while not guaranteed, is supported by current technical data.
Both approaches leverage the volume anomaly on Pfizer—a pattern recognized by experienced traders as an opportunity to implement sophisticated options strategies. The key remains in careful selection based on market outlook and risk tolerance.